Valbiotis annonce le large succès de l’étude clinique de Phase II HEART
Phase 2 SCOPE trial of SCIB1 vaccine in metastatic melanoma patients expanded
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy
Un risque réel de pénurie de dispositifs médicaux
